ondasdechoque.org
PT-BR

Diabetic ulcers with an experimental dose schedule · Randomized trial · 2013

Does adding shockwave help diabetic leg and foot ulcers shrink?

In this trial, wounds shrank in both groups over 12 weeks: from about 9 to 2 cm² with three shockwave sessions, one a week, added to wound care, and from about 8 to 5 cm² with wound care alone.

adults with diabetic leg or foot ulcers
40
shockwave sessions, one a week
3
weeks of follow-up
12

Good to know: Some of the paper's graphs and statistics don't match its tables.

Adel A. Nossair; Marwa M. Eid; Amr B. Salama Journal of American Science, 2013 · Read the paper ↗

How this study worked

Shockwave + wound care20 peopleWound care alone20 people
People were assigned to the groups by lot. Each dot is one person.

What happened

Wound size

Wound area in cm² · start and after 12 weeks

StartAfter 12 weeks

Wounds shrank in both groups: from about 9 to 2 cm² with shockwave added to wound care, and from about 8 to 5 cm² with wound care alone.
Show the numbers
GroupPeopleStartAfter 12 weeks
Shockwave + wound care208.861.92
Wound care alone208.324.65

The treatment

Shockwave + wound care

Unfocused, once a week for 3 weeks

Unfocused wavesSpread over a wider area of tissue instead of meeting at one point
Sessions
3, one a week
Pulses
500 per area · each cm² of wound
Strength
0.1mJ/mm² as reported in the paper
Numbing
Not mentioned
Device
BTL-5000 SWT Power
Everyone also got
Usual medical and wound care: wound cleaning, pressure relief and infection treatment

Compared with: The same medical and wound care without shockwave

Settings are what each study used, not a prescription.

Who took part

40 adults aged 40–70 with diabetic leg or foot ulcers present for at least 3 months, without poor blood flow; 20 per group, all finished.

Shockwave + wound care20 people
Wound care alone20 people

Side effects

The study does not report side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

40 adults aged 40–70 with diabetic lower-limb ulcers ≥3 months, 1–20 cm², grade 2/3; 20 per group, all completed. Vascular insufficiency excluded.

Shockwave treatment20randomized

Participant counts; outcome-specific denominators remain in each panel.

Control20randomized

Participant counts; outcome-specific denominators remain in each panel.

Residual wound area1 reported outcome
01
12 weeks

Residual wound area

Residual wound area cm²

means
GroupnBaselineFollow-up
Shockwave treatment208.86 (SD 3.41)1.92 (SD 3.28)
Control208.32 (SD 3.88)4.65 (SD 3.43)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Table means preserved; incompatible graph and t/p reporting prevent confident inference.

Analysis details and source

Table means preserved; incompatible graph and t/p reporting prevent confident inference.

Reported epithelialization percentage1 reported outcome
02
12 weeks

Reported epithelialization percentage

Reported epithelialization percentage % wound area

means
GroupnBaselineFollow-up
Shockwave treatment20—83.26 (SD 27.43)
Control20—48.66 (SD 31.68)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean percentage of wound area healed, not proportion of people completely healed.

Analysis details and source

Mean percentage of wound area healed, not proportion of people completely healed.

How treatment was delivered
Reported protocol

BTL-5000 SWT Power, called unfocused; 500 pulses/cm², 0.1 mJ/mm², three weekly sessions; sterile gel/drape and moving head over wound/edges. Frequency/anesthesia not stated; device-energy correspondence unresolved.

HARMS & TOLERABILITY

Patients were asked to report side effects, but no adverse-event count or structured safety results are supplied. Safety claims are therefore weakly supported.

LIMITS OF THE ANALYSIS

Randomization method, concealment and assessor blinding unreported. Table 1 t=2.57 with p=.0001 is internally questionable; prose says p<.01. Figure 1 prints 5.92 instead of table 1.92 and chart labels conflict; Figure 2 labels reverse values. Use Table 1 descriptively without accepting exact significance. No funding/conflict statement located.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Randomization method, concealment and assessor blinding unreported. Table 1 t=2.57 with p=.0001 is internally questionable; prose says p<.01. Figure 1 prints 5.92 instead of table 1.92 and chart labels conflict; Figure 2 labels reverse values. Use Table 1 descriptively without accepting exact significance. No funding/conflict statement located.
Research review

Source-linked critical reading

Randomized trials

Reading depthMaterial consulted
Technical source record

Full source read: body, methods, results, all tables and figure captions, discussion and references. The paper has no funding or conflict-of-interest statement and cites no supplementary material.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Trial reporting random assignment of 40 adults, 20 per group, to shockwaves plus wound care or wound care alone, assessed after 12 weeks.

Participants and setting

40 adults aged 40–70 with diabetic lower-limb ulcers ≥3 months, 1–20 cm², grade 2/3; 20 per group, all completed. Vascular insufficiency excluded.

Treatment delivered

Three weekly shockwave sessions in addition to usual medical/wound care.

What was compared

Medical treatment, debridement, pressure relief and infection treatment alone.

Outcomes and timing

Wound area was measured by planimetry, averaging three tracings at baseline and 12 weeks. The authors calculated the percentage of epithelialization from change in area; this is not a count of completely healed patients.

Results in context

Table 1 wound area decreased 8.86±3.41 to 1.92±3.28 cm² with ESWT and 8.32±3.88 to 4.65±3.43 with control. Reported epithelialization percentages 83.26±27.43 versus 48.66±31.68 at 12 weeks.

Harms and tolerability

Patients were asked to report side effects, but no adverse-event count or structured safety results are supplied. Safety claims are therefore weakly supported.

Limits and disclosures

Randomization method, concealment and assessor blinding unreported. Table 1 t=2.57 with p=.0001 is internally questionable; prose says p<.01. Figure 1 prints 5.92 instead of table 1.92 and chart labels conflict; Figure 2 labels reverse values. Use Table 1 descriptively without accepting exact significance. No funding/conflict statement located.

Clinical applicability

Small selected sample and source inconsistencies limit confidence. The BTL device is called unfocused in the paper; physical modality and energy reporting need verification.

What a next study should resolve

A registered trial should clarify allocation and device settings, publish consistent wound-area tables and figures, and record complete closure, infection and treatment-related adverse events.

THE ORIGINAL SOURCE

Read the original article.

Advanced Protocol of Shock Wave Therapy for Diabetic Foot Ulcer

Adel A. Nossair; Marwa M. Eid; Amr B. Salama · Journal of American Science · 2013

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →